

# Inhye E Ahn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8960741/publications.pdf>

Version: 2024-02-01

55  
papers

1,771  
citations

471061

17  
h-index

276539

41  
g-index

55  
all docs

55  
docs citations

55  
times ranked

2514  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. <i>Blood</i> , 2017, 129, 1469-1479.	0.6	276
2	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	0.6	248
3	Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. <i>Blood</i> , 2018, 131, 2357-2366.	0.6	166
4	Atypical <i>Pneumocystis jirovecii</i> pneumonia in previously untreated patients with CLL on single-agent ibrutinib. <i>Blood</i> , 2016, 128, 1940-1943.	0.6	149
5	Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. <i>Blood</i> , 2021, 137, 185-189.	0.6	110
6	Ibrutinib for Chronic Lymphocytic Leukemia with <i>TP53</i> Alterations. <i>New England Journal of Medicine</i> , 2020, 383, 498-500.	13.9	84
7	A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. <i>Blood</i> , 2018, 132, 521-532.	0.6	81
8	Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. <i>Journal of Clinical Oncology</i> , 2021, 39, 576-585.	0.8	74
9	Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. <i>Blood</i> , 2020, 136, 93-105.	0.6	68
10	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 681-697.	4.2	65
11	Temporal differential effects of proinflammatory cytokines on osteoclastogenesis. <i>International Journal of Molecular Medicine</i> , 2013, 31, 769-777.	1.8	49
12	Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Haematologica</i> , 2016, 101, e254-e258.	1.7	40
13	Targeting Bruton's Tyrosine Kinase in CLL. <i>Frontiers in Immunology</i> , 2021, 12, 687458.	2.2	40
14	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 630-647.	2.6	30
15	Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with <i>TP53</i> aberrations: a pooled analysis from four clinical trials. <i>British Journal of Haematology</i> , 2022, 196, 947-953.	1.2	28
16	Using high-sensitivity sequencing for the detection of mutations in BTK and <i>PLCÎ²2</i> genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors. <i>Oncotarget</i> , 2017, 8, 17936-17944.	0.8	26
17	Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. <i>Blood</i> , 2019, 133, 2452-2455.	0.6	22
18	Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with ibrutinib. <i>Clinical Cancer Research</i> , 2021, 27, 4531-4538.	3.2	20

#	ARTICLE	IF	CITATIONS
19	Cost analysis of asymmetric sensorineural hearing loss investigations. <i>Laryngoscope</i> , 2010, 120, 1832-1836.	1.1	17
20	Periarticular Osteoporosis Is a Prominent Feature in Early Rheumatoid Arthritis: Estimation Using Shaft to Periarticular Bone Mineral Density Ratio. <i>Journal of Korean Medical Science</i> , 2013, 28, 287.	1.1	17
21	BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. <i>Blood</i> , 2021, 138, 1843-1854.	0.6	17
22	Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2020, 61, 2375-2382.	0.6	16
23	Radiologic observation: repair of focal bone erosions after humanized antitumor necrosis factor antibody adalimumab therapy in a patient with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2010, 29, 211-213.	1.0	14
24	Impact of Genes Highly Correlated with <i>MMSET</i> Myeloma on the Survival of Non- <i>MMSET</i> Myeloma Patients. <i>Clinical Cancer Research</i> , 2016, 22, 4039-4044.	3.2	14
25	Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2017, 1, 2433-2443.	2.5	12
26	Cardiovascular adverse events of ibrutinib. <i>Blood</i> , 2019, 134, 1881-1882.	0.6	11
27	Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Clinical Cancer Research</i> , 2021, 27, 4624-4633.	3.2	10
28	Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features. <i>Leukemia and Lymphoma</i> , 2020, 61, 3177-3187.	0.6	9
29	Controversies in multiple myeloma: Evidence-based update. <i>Seminars in Oncology</i> , 2016, 43, 666-675.	0.8	6
30	Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4424-4424.	0.6	6
31	Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. <i>Blood</i> , 2018, 132, 1874-1874.	0.6	6
32	Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I). <i>Blood</i> , 2019, 134, 3053-3053.	0.6	5
33	Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial. <i>Blood</i> , 2021, 138, 2642-2642.	0.6	5
34	Ibrutinib Increases the Clonality of TCR Repertoire in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 238-238.	0.6	4
35	Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib. <i>Blood</i> , 2018, 132, 186-186.	0.6	4
36	ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 2634-2634.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 519-522.	0.6	3
38	A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2020, 95, E310-E313.	2.0	3
39	Prognostic Models Predictive of Disease Progression in CLL Patients Treated with Ibrutinib. <i>Blood</i> , 2016, 128, 187-187.	0.6	3
40	The silent progression of metastatic malignancy during the treatment with soluble tumor necrosis factor receptor. <i>Clinical Rheumatology</i> , 2010, 29, 225-227.	1.0	2
41	Activity of CD19/CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2017, 130, 799-799.	0.6	2
42	A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib. <i>Blood</i> , 2019, 134, 2861-2861.	0.6	2
43	Safety profiles of novel agent therapies in CLL. Hematology American Society of Hematology Education Program, 2017, 2017, 354-357.	0.9	1
44	Risk-Adapted Induction and Maintenance with Ofatumumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2015, 126, 1750-1750.	0.6	1
45	Diverging Clonal Evolution during Sequential Therapy with Chemoimmunotherapy Followed By BTK Inhibitors. <i>Blood</i> , 2019, 134, 850-850.	0.6	1
46	Dual antibody immunohistochemistry: an efficient and sensitive tool for the detection of residual disease in chronic lymphocytic leukemia. <i>Journal of Hematopathology</i> , 2019, 12, 183-190.	0.2	0
47	Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1816-1827.	0.6	0
48	Old Prognostic Markers Still Have a Role in CLL Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S139-S141.	0.2	0
49	Combination Treatment of Essential Thrombocythemia with Hydroxyurea and Anagrelide. <i>Blood</i> , 2011, 118, 5177-5177.	0.6	0
50	Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect® CLL Registry. <i>Blood</i> , 2016, 128, 3581-3581.	0.6	0
51	Durable Responses to Single-Agent Ibrutinib in Monoallelic but Not in Biallelic TP53 Aberrated Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 3111-3111.	0.6	0
52	Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib Show Expansion of T-Cell Clonotypes Composed of Antitumor Cytotoxic CD8+ T-Cells. <i>Blood</i> , 2019, 134, 3030-3030.	0.6	0
53	Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study. <i>Blood</i> , 2019, 134, 5474-5474.	0.6	0
54	Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance. <i>Blood</i> , 2019, 134, 1287-1287.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine. Blood, 2021, 138, 1556-1556.	0.6	0